Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/VI versus VI for bone mineral density in moderate COPD
2012-004801-28Phase 4Completed
- Sponsor
- GSK
- Start
- Oct 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Fluticasone furoate + vilanterol with Vilanterol (2 arms). Primary endpoint: Bone mineral density at the total hip. Started Oct 2013; status: completed.
02
Drugs
fluticasonevilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-004801-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004801-28.